RetinaLogik Inc. has completed a $1.1 million funding round and received Health Canada’s Class II medical device approval for its virtual reality (VR)-artificial intelligence (AI)-powered platform.

The funding and approval will accelerate the adoption of RetinaLogik’s platform, which aims to bolster the efficiency of essential optical tests—including visual field exams—and enhance patients’ experiences via a portable headset.

“Achieving these milestones marks a proud moment for our organization. We’ve developed a solution that not only makes eye care more efficient but also more affordable and accessible,” RetinaLogik CEO Dr. Sarhan said. “With the support of our investors and partners, we’re excited to continue growing and improving the future of eye care for everyone. This is just the start…”

The ISO-13485 and MDSAP certified, U.S. Food and Drug Administration-registered test is designed with patient comfort in mind, offering a streamlined testing process that significantly reduces both exam time and equipment costs. The company claims the RetinaLogik system can reduce upfront costs by up to 90% compared to traditional equipment. The product also features multilingual support, helping to bridge communication gaps in the clinic.

“We have proudly supported the RetinaLogik team since their earliest stages and are thrilled to deepen our commitment by doubling down on our investment in the company. Over the past two years, the RetinaLogik team has built a VR platform that delivers unparalleled clinical reliability for functional eye exams,” Nikhi Operating Partner UCeed Funds stated.

The milestones reaffirms RetinaLogik’s commitment to advancing high-quality vision screening and monitoring to provide more insights for specialists. The company plans to expand adoption of its platform across North America and beyond to foster earlier detection and treatment of vision-threatening conditions, and helping to prevent irreversible vision loss.

“Spring Impact Capital is proud to have co-led this [funding] round for RetinaLogik, which is proving strong market demand for its product,” said Graham Day, managing partner, Spring Impact Capital. “By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are set to make a meaningful impact on communities while achieving commercial success. We’re excited to support Abdullah, Julia, and the team in this next phase.”

“Alberta Innovates congratulates RetinaLogik on obtaining it’s Health Canada Class II licence through support from the Accelerating Innovations into CarE (AICE) program,” Health in Alberta Innovates Vice President Trevor Lynn added. “This accomplishment is an example of Alberta’s success commercializing health innovation to improve the patient experience and enable easier patient care access in the community.”